OpGen

OpGen EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of OpGen (OPGN) as of Oct 27, 2026 is 63.14 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 4.05 % — a change of 1,457.39% (higher).

EBIT/Assets

63.14 %

YoY

1,457.39%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of OpGen is 2025 63.14 % . Operating Income to Assets Ratio (EBIT/Assets) of OpGen was 2024 4.05 % . It decreases by 1,457.39% higher compared to the previous year.

The OpGen EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-147.26 USD
Jan 1, 2019
-117.74 USD
Jan 1, 2020
-43.21 USD
Jan 1, 2021
-32.47 USD
Jan 1, 2022
-86.02 USD
Jan 1, 2023
-833.46 USD
Jan 1, 2024
4.05 USD
Jan 1, 2025
63.14 USD
The OpGen EBIT/Assets history
YEAREBIT/AssetsYoY
63.14 %+1,457.39%
4.05 %-100.49%
-833.46 %+868.94%
-86.02 %+164.88%
-32.47 %-24.84%
-43.21 %-63.31%
-117.74 %-20.04%
-147.26 %-36.03%
-230.20 %+8.80%
-211.59 %+100.38%
-105.60 %-49.62%
-209.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Operating Income to Assets Ratio (EBIT/Assets) of OpGen is 63.14 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of OpGen changed from 4.05 % to 63.14 %, representing a 1,457.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) OpGen since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — OpGen

All Key Metrics — OpGen